Incomplete Freund's adjuvant
- Generic Name
- Incomplete Freund's adjuvant
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- Y9DQK7DB5U
- Associated Conditions
- -
- Associated Therapies
- -
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Skin CancerMelanoma
- Interventions
- Drug: Montanide ISA 51 VGProcedure: RadiationDrug: AldesleukinDrug: FludarabineDrug: CyclophosphamideGenetic: Anti-MART-1 F5 TCR PBL
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT00923195
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Phase 2
Completed
- Conditions
- Iris MelanomaStage IIC MelanomaStage IV MelanomaExtraocular Extension MelanomaStage IIIC MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeStage IIB MelanomaStage IIIA MelanomaStage IIIB Melanoma
- Interventions
- Biological: tyrosinase peptideBiological: gp100 antigenBiological: MART-1 antigenBiological: incomplete Freund's adjuvantDrug: Montanide ISA 51 VGBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00089063
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00080353
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
- First Posted Date
- 2003-04-28
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT00059475
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous Leukemia
- Interventions
- Biological: PR1 leukemia peptide vaccineDrug: Montanide ISA 51 VGBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00004918
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase 3
Completed
- Conditions
- Recurrent MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma
- Interventions
- Biological: AldesleukinOther: Quality-of-Life AssessmentBiological: gp100 AntigenOther: Questionnaire AdministrationDrug: Montanide ISA 51 VGOther: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 185
- Registration Number
- NCT00019682
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath